HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

These side effects have been notably milder when compared to an inhibitor of the two bromodomains. An in depth molecular analysis also discovered that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen Taylor- "Our study exposed the vital part in the KLF16/MYC regulatory axis in modulating tumor